The Archer® Reveal ctDNA™ 28 Kit for Illumina® is an advanced and user-friendly solution for targeted next generation sequencing (NGS) of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly found mutated in solid tumor type cancers.
The Reveal ctDNA reagent kit preferentially amplifies highly fragmented circulating tumor DNA (ctDNA) over larger genomic fragments (i.e. lysed WBCs) that would otherwise compromise sensitive variant detection. Single-use lyophilized reactions in a convenient 1-day workflow requiring ~1 hour of total hands-on time dramatically simplifies complex NGS library preparation procedures, reduces the chance of operator error and improves overall inter-assay reproducibility.
Powerful and simple-to-use Archer Analysis software ensures sensitive and accurate mutation detection, complete data ownership and in-house data analysis, providing a useful alternative to send-out services that require high sample input volumes and have long turnaround times.
For Research Use Only. Not for use in diagnostic procedures.
AB0088 - HS 8 reactions
AB0089 - Starter kit, HS 16 reactions
AB0090 - HS 48 reactions
AB0106 - Concordance Kit, HS 16 reactions
*Full exon coverage
Now you can do paired multiplex analysis of FFPE and liquid biopsy samples.
The Archer Reveal ctDNA 28 Concordance Kit combines Archer VariantPlex™ with Reveal ctDNA 28 for powerful copy number and variant detection from solid tumors and sensitive mutation detection from ctDNA, respectively. The kit also includes the Archer PreSeq™ DNA QC Assay to prescreen DNA FFPE samples prior to library prep.
Concordance Kit Contents:
Input cfDNA Required
Total Time Required
# of GSP2 Primers
Targeted Bases Covered
Raw molecular on-target
Recommended Read Depth
ctDNA comprises only a small fraction of cfDNA. Considering that driver mutations are often low-frequency mutations (AF < 2%), detecting such low-abundance mutations in highly fragmented material can be challenging.
The Reveal ctDNA 28 kit detects relevant ctDNA variants at allelic frequencies (AF) down to 0.1%, demonstrating the high sensitivity of the assay.
The Archer Reveal ctDNA 28 kit was used to create libraries from reference standards comprised of 8 variants at specific allelic frequencies (5%, 1% and 0.1%; HD780, Horizon Discovery) and AF values calculated. *expected AF
Low-frequency mutation detection requires increased sequencing depth, which intrinsically results in more sequencing errors and greater noise in the data that leads to false-positive calls. In AMP chemisty, template DNA fragments are ligated to molecular barcodes, which the Archer Analysis bioinformatics platform uses for read provenance to correct for PCR and sequencing errors, thus reducing false-positive calls.
Libraries were created with the Archer Reveal ctDNA 28 kit using a 0% AF reference standard, and the number of unique supporting reads with and without error correction were reported. The dotted line indicates the minimum number of unique reads (ten) to call a variant.
ctDNA abundance in liquid biopsy samples varies across solid tumor types and disease states. The Reveal ctDNA 28 kit enables accurate variant detection across a wide range of input masses, demonstrating assay flexibility that is necessary for liquid biopsy research.
Libraries were created with the Archer Reveal ctDNA 28 kit using different input masses of the reference standards at 5%, 1% and 0.1% expected AF. Mean AF values across 8 variants in the reference standards were reported above. Dotted lines indicate expected AF.
AMP is designed with simplicity in mind. The Reveal ctDNA 28 kit uses benchtop-stable lyophilized reagents in single-use 8-tube strips for flexible run sizes and minimun cross-contamination. The workflow comprises serial transfers that total 1 hour of hands-on time for single-day library prep.
Consistent assay performance is a hallmark of Archer NGS assays, and the Archer Reveal ctDNA 28 is no exception, even with low AF variants.
Libraries were created with the Archer Reveal ctDNA 28 kit using reference standards at 5%, 1% and 0.1% expected AF. NRAS A59T AF values for each replicate were reported above. Dotted lines indicate expected AF.
2477 55th Street, Suite 202
Boulder, CO 80301